Reaction profile

The FDA adverse-event record for metastatic tumour

Name: Metastatic tumour - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

48 FDA reports name metastatic tumour, a lower-volume reaction in the CVM extract (VeDDRA 1927). Plate stamps and neighbourhood peers follow.

#1759 of 2,481
by report volume (all reactions): 48
reports citing this reaction: 66.7%
death-coded share: Dog
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Metastatic tumour has 48 reports now versus 47 in that prior snapshot: 1 more (2.1%).

Report change: +1
Death-coded reports: +0
Death-coded share: −1.4 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Metastatic tumour changes

FDA AER · VeDDRA plate

Code 1927 VOL-TRACE

VOL-TRACE · DEATH-HOT · MID-PACK · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

VOL-TRACE 48 reports
DEATH-HOT 66.7%
MID-PACK #1759/2481
PHOTO-FINISH Abnormal echocardiogr…
SPECIES-DOG Dog · 40
DRUG-LEAD Oclacitinib Malea… · 12
DESK-WIDE 20 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: Abnormal echocardiogram (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around Metastatic tumour

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around Metastatic tumour

Metastatic tumour: high death-coded share in the FDA AER plate

Signature read: Metastatic tumour's 66.7% death-coded share is among the highest in the openFDA reaction corpus. Report volume is lower-third scale: 48 named reports in the openFDA extract. Death-coded share is upper-third: 32 of 48 reports (66.7% of named reports). Nearest volume peer: Abnormal echocardiogram (±0 reports). Lead species Dog (40). Lead co-reported drug Oclacitinib Maleate (12).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 40

Cat 8

Breeds Most Affected

Retriever - Golden 4

Domestic Shorthair 4

Retriever - Labrador 3

Shepherd Dog - German 3

Siberian Husky 2

Crossbred Canine/dog 2

Shih Tzu 2

Terrier (unspecified) 2

Mastiff 2

Dog (unknown) 2

Associated Drugs

Oclacitinib Maleate 12

Trilostane 8

Carprofen 5

Milbemycin Oxime + Spinosad 4

Prednisone 4

Gabapentin 4

Robenacoxib 4

Imidacloprid + Moxidectin 3

Mirtazapine 3

Bedinvetmab 3

Anesthesia 2

Fluralaner Chew Tablets 2

Pimobendan 2

Tigilanol Tiglate 2

Milbemycin Oxime + Praziquantel 2

Buprenorphine 2

Cefovecin Sodium 2

Molidustat Sodium 2

Fluid Therapy 2

Prescription Renal Diet 2

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Metastatic tumour (#1759 of 2,481 by report volume); death-coded 66.7%. PlainBreed reaction plate · death-coded share stamp 66.7% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →